Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | CCR1 | P32246 | 1/20 | 0.46 |
| ▸ | CCR5 | P51681 | 1/20 | 0.46 |
| ▸ | CCR8 | P51685 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | NOS2 | P35228 | 1/20 | 0.43 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | BIRC2 | Q13490 | 1/20 | 0.42 |
| ▸ | P4HTM | Q9NXG6 | 3/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | NPC1 | O15118 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.41 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL247414 | 0.98 | RAB9A (0.47) | RAB9AMAPTALDH1A1CCR1CCR5 | |
| SCHEMBL14826038 | 0.84 | EGLN1 (0.58) | RAB9AALDH1A1KCNJ1KDM4EP4HTM | |
| SCHEMBL82620 | 0.82 | P4HTM (0.59) | RAB9AMAPTALDH1A1CCR1CCR5 | |
| SCHEMBL29954297 | 0.82 | P4HTM (0.59) | RAB9AMAPTALDH1A1CCR1CCR5 | |
| SCHEMBL2270351 | 0.80 | P4HTM (0.57) | RAB9AMAPTALDH1A1CCR1CCR5 | |
| SCHEMBL171039 | 0.80 | KMT2A (0.53) | RAB9AMAPTALDH1A1CCR1CCR5 | |
| SCHEMBL10934402 | 0.80 | RAB9A (0.47) | RAB9AMAPTALDH1A1CCR1CCR5 | |
| SCHEMBL3997731 | 0.80 | P4HTM (0.57) | RAB9AMAPTALDH1A1CCR1CCR5 | |
| SCHEMBL3997737 | 0.80 | P4HTM (0.57) | RAB9AMAPTALDH1A1CCR1CCR5 | |
| Hydrochloric Acid SCHEMBL5955817 | 0.80 | P4HTM (0.57) | RAB9AMAPTALDH1A1CCR1CCR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 375 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4581071-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2025-07-09 | — | — | EP | claimed |
| WO-2024046712-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2024-03-07 | — | — | WO | claimed |
| CN-110423234-B | Thiosemicarbazone derivative containing indole fragment and preparation method and application thereof | 郑州大学 | 2020-06-30 | — | — | CN | claimed |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | EMORY UNIVERSITY (US) | 2026-03-24 | — | — | US | disclosed |
| EP-4709725-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | Progentos Therapeutics, Inc. (US) | 2026-03-18 | — | — | EP | disclosed |
| EP-4581071-A1 | METHOD FOR PRODUCING A MATERIAL FOR A MEMBRANE, MATERIAL, MEMBRANE AND USE OF A MEMBRANE | Forschungszentrum Jülich GmbH (DE) | 2025-07-09 | — | — | EP | disclosed |
| EP-3713931-B1 | 3-OXO-6-HETEROARYL-2-PHENYL-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES | DEUTSCHES KREBSFORSCH (DE) | 2025-03-05 | — | — | EP | disclosed |
| WO-2024233642-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PROGENTOS THERAPEUTICS, INC. (US) | 2024-11-14 | — | — | WO | disclosed |
| US-20240316034-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | UNIV EMORY (US) | 2024-09-26 | — | — | US | disclosed |
| WO-2024174819-A1 | HETEROARYL-CONTAINING UNNATURAL AMINO ACID AND USE THEREOF | 浙江新码生物医药有限公司 | 2024-08-29 | — | — | WO | disclosed |
| CN-117417292-B | Heteroaryl-containing unnatural amino acid and application thereof | 浙江新码生物医药有限公司 | 2024-07-12 | — | — | CN | disclosed |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | ANORMED CORPORATION (CA) | 2004-10-21 | — | — | US | disclosed |
| EP-0974602-B1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR CORP (JP) | 2004-01-02 | — | — | EP | disclosed |
| EP-1361224-A1 | Heterocyclic hydrazones for use as anti-cancer agents | Innovationsagentur Gesellschaft m.b.H. (AT) | 2003-11-12 | — | — | EP | disclosed |
| US-20030166658-A1 | Heterocyclic hydrazones for use as anti-cancer agents | EASMON, JOHNNY, OF INSTITUT FUR PHARMAZIE (AT) | 2003-09-04 | — | — | US | disclosed |
| EP-1286987-A1 | HETEROCYCLIC HYDRAZONES FOR USE AS ANTI-CANCER AGENTS | Austria Wirtschaftsservice Gesellschaft mit beschränkter Haftung (AT) | 2003-03-05 | — | — | EP | disclosed |
| WO-2001094340-A1 | HETEROCYCLIC HYDRAZONES FOR USE AS ANTI-CANCER AGENTS | INNOVATIONSAGENTUR GESELLSCHAFT M.B.H. (AT) | 2001-12-13 | — | — | WO | disclosed |
| US-6291596-B1 | CONTACTING OLEFINICALLY UNSATURATED COMPOUND WITH HYDROGEN IN THE PRESENCE OF A HYDROGENATION CATALYST COMPRISING TITANIUM OR ZIRCONIUM OR HAFNIUM COMPOUND IN AN INERT, ORGANIC SOLVENT | JSR CORPORATION (JP) | 2001-09-18 | — | — | US | disclosed |
| EP-0974602-A1 | Catalyst and process for hydrogenating olefinically unsaturated compound | JSR Corporation (JP) | 2000-01-26 | — | — | EP | disclosed |
| US-4574125-A | Naphtho-[1,2-b]-quinolizium derivatives as antidiarrheal agents | MERCK & CO., INC. (US) | 1986-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240316034-A1 | Chemokine CXCR4 Receptor Modulators and Uses Related Thereto | CXCR4, CXCL12, CXCR1 | RAB9A 1165/4885MAPT 3787/4885ALDH1A1 1760/4885 |
| US-20030166658-A1 | Heterocyclic hydrazones for use as anti-cancer agents | HDAC5, AADAC, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | RAB9A 3481/4885MAPT 4586/4885ALDH1A1 436/4885 |
| US-20040209921-A1 | CXCR4 chemokine receptor binding comounds | CXCR4, CXCR1, CXCR3 | RAB9A 899/4885MAPT 4625/4885ALDH1A1 357/4885 |
| US-12582645-B2 | Chemokine CXCR4 receptor modulators and uses related thereto | CXCR4, CXCR2, CXCR1 | RAB9A 1727/4885MAPT 3767/4885ALDH1A1 3100/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.